CP 47,497: Difference between revisions

Latest revision as of 03:30, 13 February 2025

CP 47,497[edit]

CP 47,497 is a synthetic cannabinoid that was developed in the 1980s by Pfizer as part of research into the endocannabinoid system. It is a potent agonist of the cannabinoid receptors, particularly the CB1 receptor.

Chemical Properties[edit]

CP 47,497 is a member of the cyclohexylphenol class of cannabinoids. Its chemical structure is characterized by a cyclohexyl group attached to a phenol moiety, which is similar to the structure of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Pharmacology[edit]

CP 47,497 acts as a full agonist at the CB1 receptor, which is primarily found in the central nervous system. This interaction is responsible for its psychoactive effects, which mimic those of THC. The compound also has affinity for the CB2 receptor, which is more prevalent in the immune system.

Effects[edit]

The effects of CP 47,497 are similar to those of THC, including euphoria, relaxation, and altered perception. However, due to its synthetic nature, the potency and duration of effects can vary significantly compared to natural cannabinoids.

Legal Status[edit]

Due to its psychoactive properties and potential for abuse, CP 47,497 has been classified as a controlled substance in many countries. It is often included in legislation targeting synthetic cannabinoids, which are sometimes sold as "spice" or "K2."

Research[edit]

Research into CP 47,497 and similar compounds has provided valuable insights into the functioning of the endocannabinoid system. These studies have implications for the development of new therapeutic agents targeting cannabinoid receptors.

Related pages[edit]

@@ Line 1: / Line 1: @@
-'''CP 47,497''' is a [[cannabinoid]] receptor [[agonist]] drug, which is a type of drug that interacts with the cannabinoid receptors in the body. It was first synthesized in the 1980s by the pharmaceutical company [[Pfizer]]. CP 47,497 is one of the most potent cannabinoids in existence, and it has been used in scientific research to study the effects of cannabinoids on the body.
+== CP 47,497 ==
-== History ==
+[[File:CP-47,497.svg|thumb|right|Chemical structure of CP 47,497]]
-CP 47,497 was first synthesized by a team of researchers at [[Pfizer]] in the 1980s. The drug was developed as part of a research program into cannabinoids, which are a group of compounds that interact with the cannabinoid receptors in the body. Cannabinoids are most commonly associated with [[cannabis (drug)|cannabis]], but they can also be found in other plants and can be synthesized in a laboratory.
+'''CP 47,497''' is a synthetic [[cannabinoid]] that was developed in the 1980s by [[Pfizer]] as part of research into the [[endocannabinoid system]]. It is a potent agonist of the [[cannabinoid receptor]]s, particularly the [[CB1 receptor]].
+== Chemical Properties ==
+CP 47,497 is a member of the [[cyclohexylphenol]] class of cannabinoids. Its chemical structure is characterized by a cyclohexyl group attached to a phenol moiety, which is similar to the structure of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]].
 == Pharmacology ==
-CP 47,497 is a [[cannabinoid receptor]] agonist, which means that it binds to and activates the cannabinoid receptors in the body. There are two main types of cannabinoid receptors, known as CB1 and CB2. CB1 receptors are primarily found in the brain and central nervous system, while CB2 receptors are primarily found in the immune system.
+CP 47,497 acts as a full agonist at the CB1 receptor, which is primarily found in the [[central nervous system]]. This interaction is responsible for its psychoactive effects, which mimic those of THC. The compound also has affinity for the [[CB2 receptor]], which is more prevalent in the [[immune system]].
+== Effects ==
+The effects of CP 47,497 are similar to those of THC, including [[euphoria]], [[relaxation]], and altered perception. However, due to its synthetic nature, the potency and duration of effects can vary significantly compared to natural cannabinoids.
+== Legal Status ==
-When CP 47,497 binds to the CB1 receptors, it can produce a range of effects, including pain relief, relaxation, and changes in perception. When it binds to the CB2 receptors, it can affect the immune system, potentially reducing inflammation and pain.
+Due to its psychoactive properties and potential for abuse, CP 47,497 has been classified as a controlled substance in many countries. It is often included in legislation targeting synthetic cannabinoids, which are sometimes sold as "[[spice (drug)|spice]]" or "[[K2 (drug)|K2]]."
-== Legal status ==
+== Research ==
-The legal status of CP 47,497 varies by country. In the United States, it is classified as a Schedule I controlled substance, which means it is illegal to manufacture, distribute, or possess without a license from the Drug Enforcement Administration. In other countries, such as the United Kingdom and Canada, it is also controlled under their respective drug laws.
+Research into CP 47,497 and similar compounds has provided valuable insights into the functioning of the endocannabinoid system. These studies have implications for the development of new therapeutic agents targeting cannabinoid receptors.
-== See also ==
+== Related pages ==
-* [[Cannabinoid]]
 * [[Cannabinoid receptor]]
-* [[Pfizer]]
+* [[Synthetic cannabinoids]]
+* [[Endocannabinoid system]]
+* [[Tetrahydrocannabinol]]
-[[Category:Drugs]]
+[[Category:Synthetic cannabinoids]]
-[[Category:Cannabinoids]]
 [[Category:Pfizer]]
-{{Pharma-stub}}
-{{No image}}